Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results

MLA

Claire F. Verschraegen, et al. “Pegylated Liposomal Doxorubicin (PLD) with Bevacizumab (B) in Second-Line Treatment of Ovarian Cancer (OC): Pharmacokinetics (PK), Safety, and Preliminary Outcome Results.” Journal of Clinical Oncology, vol. 27, May 2009, p. 5548. EBSCOhost, https://doi.org/10.1200/jco.2009.27.15_suppl.5548.

APA

Claire F. Verschraegen, Stephanie V. Blank, Carolyn Y. Muller, Leonard Liebes, Leslie R. Boyd, Teresa Rutledge, Bhavana Pothuri, F. Muggia, David A. Fishman, & Andrea Downey. (2009). Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results. Journal of Clinical Oncology, 27, 5548. https://doi.org/10.1200/jco.2009.27.15_suppl.5548

Chicago

Claire F. Verschraegen, Stephanie V. Blank, Carolyn Y. Muller, Leonard Liebes, Leslie R. Boyd, Teresa Rutledge, Bhavana Pothuri, F. Muggia, David A. Fishman, and Andrea Downey. 2009. “Pegylated Liposomal Doxorubicin (PLD) with Bevacizumab (B) in Second-Line Treatment of Ovarian Cancer (OC): Pharmacokinetics (PK), Safety, and Preliminary Outcome Results.” Journal of Clinical Oncology 27 (May): 5548. doi:10.1200/jco.2009.27.15_suppl.5548.